Study S000386

A Double-Masked, Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 2 Study to Determine the Tolerability, Pharmacokinetics, and Pharmacodynamics of the GLP 1 Agonist HM11260C in Adult Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01452451
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 72
Start: 2011-12
Primary completion: 2013-06
Lead sponsor: Hanmi Pharmaceutical Company Limited
Conditions: Diabetes Mellitus
Interventions: DRUG:HM11260C; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Number of subjects with adverse events as a measure of safety and tolerability [Up to 106 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.